Abstract: Disclosed is a polymetalloxane including a constituent unit represented by the following general formula (1), which stably exists in a transparent and uniform state in a solution and can form a homogeneous cured film: wherein R1 is an organic group and at least one of R1 is an (R33SiO—) group, R3 is optionally selected from specific groups, R2 is optionally selected from specific groups, when plural R1, R2, and R3 exist, they may be the same or different, M represents a specific metal atom, m is an integer indicating a valence of a metal atom M, and a is an integer of 1 to (m?2).
Abstract: Provided is a method capable of separating and purifying astatine-211 in a high yield and dissolving same in a solution. A method for producing astatine-211, including a step of irradiating ? ray to bismuth to produce astatine-211 in the bismuth, and a step of distilling the bismuth that received ? ray irradiation with a carrier gas containing an inert gas, O2 and H2O to separate and purify astatine-211, and dissolving the astatine-211 in a solution.
Type:
Grant
Filed:
December 7, 2018
Date of Patent:
October 24, 2023
Assignee:
OSAKA UNIVERSITY
Inventors:
Atsushi Shinohara, Atsushi Toyoshima, Takashi Yoshimura, Akimitsu Kanda
Abstract: The invention provides a (drug-containing) lipid nanoparticle with: (i) at least one phospholipid; (ii) at least one lysolipid; and (iii) at least one phospholipid comprising a hydrophilic polymer; and (iv) at least one structural lipid of formula (I) which has the following general structure: wherein R and R? are long hydrocarbyl hydrophobic chains, Y is a linker element, and PHG is a polar head group described as large according to its van der Waals radius, and which is different from the phospholipid (i). The lipid nanoparticle can release a drug (or API) from within the lipid nanoparticle as a result of focused ultrasound (FUS) applied continuously, at least twice, to a desired part of the body to induce hyperthermia (an increase in temperature). FUS is applied after the lipid nanoparticle containing the drug has been administered to the live subject, and causes controlled release of the drug at the desired site of the body.
Type:
Grant
Filed:
June 8, 2016
Date of Patent:
October 17, 2023
Assignee:
KING'S COLLEGE LONDON
Inventors:
Maria Thanou, Michael James Lee Wright, Miguel Centelles, Andrew David Miller, Wladyslaw Gedroyc
Abstract: Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems are disclosed. Certain heptamethine cyanines exhibit renal system specificity, while others exhibit biliary system specificity. The compounds may be used for diagnostic purposes and/or for visualization of renal or biliary systems during surgery.
Type:
Grant
Filed:
February 14, 2019
Date of Patent:
October 17, 2023
Assignees:
CHILDREN'S NATIONAL MEDICAL CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES
Inventors:
Martin John Schnermann, Peter C. W. Kim, Jaepyeong Cha, Roger Rauhauser Nani
Abstract: Provided herein are methods of fluorinating organic compounds. The electrochemical fluorination and radiofluorination of organic molecules using the cation pool technique is described, where the 18F and/or 19F-fluorine ions are added after the process of electrochemical oxidation, i.e., after formation of a carbocationic organic compound (i.e., a compound having a carbon atom with a positive charge).
Type:
Grant
Filed:
February 4, 2019
Date of Patent:
October 10, 2023
Assignee:
The Regents of the University of California
Abstract: The present application provides a compound comprising at least one isotopically labeled nitrogen atom for use in diagnosing a condition or disease in a subject, compositions and kits comprising the compound and methods of using the same.
Type:
Grant
Filed:
January 24, 2019
Date of Patent:
October 3, 2023
Assignee:
HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
Inventors:
Ayelet Gamliel, Talia Harris, Gal Sapir, Jacob Sosna, Moshe John Gomori, Rachel Katz-Brull
Abstract: Disclosed herein are biocontrol compositions against plant fungal pathogens and methods of use thereof for the prevention or reduction of crop loss or food spoilage. The biocontrol composition can comprise at least one microbe with anti-fungal activity or a secondary metabolite of the at least one microbe. The methods can comprise application of the biocontrol composition to a plant, a seed, or a produce thereof or to a packaging material used to transport or store the produce.
Type:
Grant
Filed:
August 11, 2020
Date of Patent:
October 3, 2023
Assignee:
Boost Biomes, Inc.
Inventors:
Robert McBride, Karen Hunt, Jamie Bacher, Veronica Garcia, James Pearce
Abstract: The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and infectious diseases, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.
Type:
Grant
Filed:
April 6, 2018
Date of Patent:
September 26, 2023
Assignee:
CENTAURI THERAPEUTICS LIMITED (GB/GB)
Inventors:
Michael Westby, Melanie Glossop, Christine Watson, Christopher Pickford
Abstract: Disclosed is a method of producing Tc-99m by using nuclear resonance fluorescence. More specifically, and a method of preparing Tc-99m by using nuclear resonance fluorescence includes irradiating a ground-state Tc-99 nucleus with a photon beam, thereby causing a nuclear transmutation to proceed such that the nucleus excited to high energy and then undergoes a transition to Tc-99m.
Type:
Grant
Filed:
September 18, 2017
Date of Patent:
September 19, 2023
Assignee:
Korea Hydro & Nuclear Power Co., Ltd.
Inventors:
Yonghee Kim, Jiyoung Lee, Seongdong Jang, Ur Rehman Haseeb, Eun Ki Lee, Young Ae Kim, Ji Eun Jung
Abstract: A nanotherapeutic supported by a hierarchical silica composite with dual imaging capability (e.g. fluorescence and magnetic resonance imaging), a method of preparing the nanotherapeutic, and a method of treating cancer. Also disclosed is a method of oxidatively dehydrogenating ethane using a catalytic system supported by a hierarchical silica composite.
Abstract: Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.
Type:
Grant
Filed:
July 3, 2018
Date of Patent:
September 12, 2023
Assignee:
IntoCell, Inc.
Inventors:
Taekyo Park, Sung Ho Woo, Sunyoung Kim, Suho Park, Jongun Cho, Doohwan Jung, Donghoon Seo, Jaeho Lee, Sangkwang Lee, Sanghyeon Yun, Hyang Sook Lee, Okku Park, Beomseok Seo
Abstract: A method for producing an 225Ac solution includes a step (I) of irradiating a 226Ra target with particles to generate two or more actinium radioisotopes (Ac) including at least 225Ac, a step (II) of dissolving the 226Ra target after the aforementioned step to obtain a solution (1), a step (III) of separating 226Ra and Ac contained in the solution (1) to obtain a solution (2), a step (IV) of allowing Ac contained in the solution (2) other than 225Ac to decay to obtain a solution (3), and a step (V) of separating Ra and Ac contained in the solution (3) to obtain a solution (4). The solution (4) is used to produce a medicine that contains, as an active ingredient, a conjugate between a chelating agent that has formed a complex with 225Ac, and a targeting agent.
Type:
Grant
Filed:
July 20, 2022
Date of Patent:
September 12, 2023
Assignees:
NIHON MEDI-PHYSICS CO., LTD., NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY
Abstract: A method for preparing a suspension of “size-controlled” gas-filled microvesicles by microfluidic manufacturing techniques, which comprises using a gaseous flow comprising a first gas having high solubility in water and a second gas having low 5 solubility in water.
Type:
Grant
Filed:
March 4, 2019
Date of Patent:
September 12, 2023
Assignee:
Bracco Suisse SA
Inventors:
Tim Segers, Emmanuel Gaud, Gilles Casqueiro, Peter Frinking, Anne Lassus
Abstract: The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
Type:
Grant
Filed:
October 25, 2019
Date of Patent:
September 5, 2023
Assignee:
Lantheus Medical Imaging, Inc.
Inventors:
Richard R. Cesati, Heike S. Radeke, Suresh K. Pandey, Ajay Purohit, Simon P. Robinson
Abstract: Aqueous formulations and kits of radiopharmaceutical compounds of general Formula (II) protected from radiolysis with stabilisers, such as L-methionine and gentisic acid, are disclosed, wherein the compounds are based on sarcophagine ligands coordinated to a radioisotope, such as 64-copper, and linked to a tetrazine group for reaction with tumour targeting antibodies having functional reactive groups such as trans-cyclooctene, processes of preparing said radioligand formulations, and uses thereof for radioimaging, diagnosing and treating cancer.
Abstract: The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and/or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.
Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a structure of: wherein L is a cleavable linker group; X is a cargo moiety-containing group; and R1 and R2 are each independently hydrogen, alkyl, or substituted alkyl; or R1 and R2 together form a boronic ester ring or a substituted boronic ester group.
Type:
Grant
Filed:
July 28, 2017
Date of Patent:
August 29, 2023
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Paul E. Floreancig, Alexander Deiters, Ramsey D. Hanna, Yuta R. Naro
Abstract: This invention relates generally to cyanine-containing compounds; pharmaceutical compositions comprising cyanine-containing compounds; and methods of using cyanine-containing compounds for cancer cell imaging, cancer cell growth inhibition, and detecting cancer cells, for example. Compounds of the invention are preferentially taken up by cancer cells as compared to normal cells. This allows many uses in the cancer treatment, diagnosis, tracking and imaging fields.
Type:
Grant
Filed:
February 2, 2017
Date of Patent:
August 29, 2023
Assignee:
Emory University
Inventors:
Leland W. K. Chung, Lucjan Strekowski, Chunmeng Shi, Maged Henary, Gabor Patonay, James J. Krutak, Xiaojian Yang, Guodong Zhu, Ruoxiang Wang, Haiyen E. Zhau